CHI Announces its Roadmap for Accelerating Commercialization of Molecular Diagnostics Short Course

Jan. 10, 2012 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute releases full details for its Roadmap for Accelerating Commercialization of Molecular Diagnostics Short Course taking place on February 20, 2012 at the Moscone North Convention Center in San Francisco, CA.  This short course is focused on development of molecular diagnostics as they make their way from biomarker discovery and initial proof of clinical performance through to commercial launch, partnership delivery and market development. The course will emphasize identification of critical hurdles that when addressed early, can materially accelerate progress.  Vital areas to be covered include product pricing, reimbursement strategies, regulatory pathway decisions, provider engagement and key opinion leader development.  Examples and case studies of molecular diagnostic companies in will be shared to illustrate a real world roadmap including:

•   Rationale for reimbursement - understanding coverage
•   Regulatory clearance and navigating claims language and timing
•   Maximizing clinical study results while addressing evolving evidence demands

Featured Speakers Include:

•   William Cook, M.B.A., Principal, Strategy and Business Development, Clinical Diagnostics, WECA
•   Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors
•   Rina Wolf, Vice President of Commercialization Strategies, Consulting & Industry Affairs, Xifen

Agenda Includes:

•   Roadmap for Accelerating Commercialization of Molecular Diagnostics (William Cook, M.B.A., WECA)
•   Route to Commercialization and Revenue Generation (Patrick F. Terry, Scientia Advisors)
•   Oxford Gene Technology Presentation
•   The Impact of the New Realities of Coverage, Coding and Pricing to Your Lab:  An Update (Rina Wolf, Xifen)

The 19th Annual Molecular Medicine Tri-Conference is taking place February 19-23 and includes 2 partnering forums, 5 symposia, 18 short courses, and 12 core programs around 4 scientific channels: diagnostics, drug discovery & development, informatics, and cancer. Over 3000 attendees and 150+ sponsors & exhibitors will gather in shared networking functions and in the exhibit/poster hall.

Advance registration discounts are available until January 13, 2012. To view the entire conference agenda and to register, please visit http://www.TriConference.com

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (http://www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.